Moderna shares positive phase 3 results for mRNA influenza vaccine candidate
Moderna has shared positive results from a late-stage trial of its influenza vaccine, with mRNA-1010 shown to generate a stronger immune response against all four World Health Organization (WHO)-recommended flu strains compared to GSK’s Fluarix.
Improved immunogenicity was observed across age groups, including older adults, and the company said the candidate was found to be safe and tolerable.
mRNA-1010 was also shown in a separate phase 1/2 head-to-head study to induce a stronger immune response against three of the four WHO-recommended strains compared to Sanofi’s high-dose Fluzone vaccine, and generated an equal response to the comparator against the fourth.
Seasonal flu is an acute respiratory infection caused by influenza viruses, which circulate in all parts of the world.
